Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

被引：9

作者：

Aredo, Jacqueline V. ^{[1
]}

Padda, Sukhmani K. ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Stanford Canc Inst, Dept Med,Div Oncol, 875 Blake Wilbur Dr, Stanford, CA 94305 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2018年 / 19卷 / 08期

基金：

英国科研创新办公室;

关键词：

KRAS mutation; Co-occurring mutation; Lung cancer; Precision medicine; Immunotherapy; PLATINUM-BASED CHEMOTHERAPY; SELUMETINIB PLUS DOCETAXEL; COOCCURRING GENOMIC ALTERATIONS; RANDOMIZED PHASE-II; MUTATION STATUS; K-RAS; CDK4/6; INHIBITOR; MEK INHIBITORS; T-CELL; ANTITUMOR-ACTIVITY;

D O I：

10.1007/s11864-018-0557-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of genomic alterations that drive the development and progression of non-small cell lung cancer (NSCLC) has transformed how we treat metastatic disease. However, the promise of precision medicine remains elusive for the most commonly mutated oncogene in NSCLC, KRAS. This is perhaps due to the substantial heterogeneity within the broader genomic context of KRAS-mutant NSCLC. At this time, approaches for treating metastatic KRAS-mutant NSCLC mirror those for treating NSCLC that lacks a known driver mutation, including standard chemotherapeutic and immunotherapeutic approaches. Ongoing research aims to define further subgroups of KRAS-mutant NSCLC based on mutation subtype and co-occurring mutations. These efforts offer the potential to optimize standard-of-care regimens within these emerging subgroups and harness innovative strategies to realize precision medicine in this setting.

引用

页数：21

共 98 条

[31] A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer [J].

Gandara, David R. ;

Leighl, Natasha ;

Delord, Jean-Pierre ;

Barlesi, Fabrice ;

Bennouna, Jaafar ;

Zalcman, Gerald ;

Infante, Jeffrey R. ;

Reckamp, Karen L. ;

Kelly, Karen ;

Shepherd, Frances A. ;

Mazieres, Julien ;

Janku, Filip ;

Gardner, Olivia S. ;

Mookerjee, Bijoyesh ;

Wu, Yuehui ;

Cox, Donna S. ;

Schramek, Dan ;

Peddareddigari, Vijay ;

Liu, Yuan ;

D'Amelio, Anthony M., Jr. ;

Blumenschein, George, Jr. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) :556-566

[32] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[33] Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer [J].

Garassino, M. C. ;

Marabese, M. ;

Rusconi, P. ;

Rulli, E. ;

Martelli, O. ;

Farina, G. ;

Scanni, A. ;

Broggini, M. .

ANNALS OF ONCOLOGY, 2011, 22 (01) :235-U277

[34] Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine [J].

Gelbert, Lawrence M. ;

Cai, Shufen ;

Lin, Xi ;

Sanchez-Martinez, Concepcion ;

del Prado, Miriam ;

Jose Lallena, Maria ;

Torres, Raquel ;

Ajamie, Rose T. ;

Wishart, Graham N. ;

Flack, Robert Steven ;

Neubauer, Blake Lee ;

Young, Jamie ;

Chan, Edward M. ;

Iversen, Philip ;

Cronier, Damien ;

Kreklau, Emiko ;

de Dios, Alfonso .

INVESTIGATIONAL NEW DRUGS, 2014, 32 (05) :825-837

[35] EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC). [J].

Goldman, Jonathan Wade ;

Liu, Haiyan ;

Vuppalapaty, Meghah ;

Wilkerson, Charles ;

Lemaire, Clementine ;

Crouse, Steve ;

Sollier-Christen, Elodie .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[36] Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer [J].

Hames, Megan L. ;

Chen, Heidi ;

Iams, Wade ;

Aston, Jonathan ;

Lovly, Christine M. ;

Horn, Leora .

LUNG CANCER, 2016, 92 :29-34

[37] Comprehensive genomic characterization of squamous cell lung cancers [J].

Hammerman, Peter S. ;

Lawrence, Michael S. ;

Voet, Douglas ;

Jing, Rui ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Stojanov, Petar ;

McKenna, Aaron ;

Lander, Eric S. ;

Gabriel, Stacey ;

Getz, Gad ;

Sougnez, Carrie ;

Imielinski, Marcin ;

Helman, Elena ;

Hernandez, Bryan ;

Pho, Nam H. ;

Meyerson, Matthew ;

Chu, Andy ;

Chun, Hye-Jung E. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Sipahimalani, Payal ;

Stoll, Dominik ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Chuah, Eric ;

Coope, Robin J. N. ;

Corbett, Richard ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Anhe Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Karen ;

Nip, Ka Ming ;

Olshen, Adam ;

Schein, Jacqueline E. ;

Slobodan, Jared R. ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard ;

Zeng, Thomas ;

Zhao, Yongjun ;

Jones, Steven J. M. .

NATURE, 2012, 489 (7417) :519-525

[38] Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome [J].

Ihle, Nathan T. ;

Byers, Lauren A. ;

Kim, Edward S. ;

Saintigny, Pierre ;

Lee, J. Jack ;

Blumenschein, George R. ;

Tsao, Anne ;

Liu, Suyu ;

Larsen, Jill E. ;

Wang, Jing ;

Diao, Lixia ;

Coombes, Kevin R. ;

Chen, Lu ;

Zhang, Shuxing ;

Abdelmelek, Mena F. ;

Tang, Ximing ;

Papadimitrakopoulou, Vassiliki ;

Minna, John D. ;

Lippman, Scott M. ;

Hong, Waun K. ;

Herbst, Roy S. ;

Wistuba, Ignacio I. ;

Heymach, John V. ;

Powis, Garth .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (03) :228-239

[39] Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer [J].

Jaenne, P. A. ;

Smith, I. ;

McWalter, G. ;

Mann, H. ;

Dougherty, B. ;

Walker, J. ;

Orr, M. C. M. ;

Hodgson, D. R. ;

Shaw, A. T. ;

Pereira, J. R. ;

Jeannin, G. ;

Vansteenkiste, J. ;

Barrios, C. H. ;

Franke, F. A. ;

Crino, L. ;

Smith, P. .

BRITISH JOURNAL OF CANCER, 2015, 113 (02) :199-203

[40] Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study [J].

Jaenne, Pasi A. ;

Shaw, Alice T. ;

Pereira, Jose Rodrigues ;

Jeannin, Gaelle ;

Vansteenkiste, Johan ;

Barrios, Carlos ;

Franke, Fabio Andre ;

Grinsted, Lynda ;

Zazulina, Victoria ;

Smith, Paul ;

Smith, Ian ;

Crino, Lucio .

LANCET ONCOLOGY, 2013, 14 (01) :38-47

← 1 2 3 4 5 6 7 8 9 10 →